Stock comparison
Enovis
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ENOV
Enovis
Market cap
$1.4B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ENOV | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 18F | 69B | LMAT |
| Benjamin Graham | 18F | 81A | LMAT |
| Philip Fisher | 27F | 73B | LMAT |
| Peter Lynch | 30F | 59C | LMAT |
| Joel Greenblatt | 0F | 48D | LMAT |
| Charlie Munger | 24F | 60C | LMAT |
| Terry Smith | 20F | 61C | LMAT |
Side-by-side metrics
| Metric | ENOV | LMAT |
|---|---|---|
| Market cap | $1.4B | $2.32B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | - | 36.6x |
| ROIC (TTM) | 1.87% | 9.43% |
| Gross margin | 56.81% | 72.39% |
| Net margin | -49.91% | 24.35% |
| Revenue CAGR 5y | 12.05% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 1.0x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ENOV leads on
- EV/EBIT-vs 36.6x+125%
- P/E (TTM)-vs 37.1x+103%
LMAT leads on
- Net margin24.35%vs -49.91%+149%
- Dividend yield0.84%vs 0.0%+100%
- ROIC (TTM)9.43%vs 1.87%+80%
- Debt / Equity0.5xvs 1.0x+51%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.